{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:33:55Z","timestamp":1793320435750,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.aohep.2026.102477","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:13:13Z","timestamp":1792797193000},"page":"102477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapy for MASLD: current evidence and challenges in clinical practice"],"prefix":"10.1016","author":[{"given":"Laura","family":"Pages","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Jimenez-Masip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tricarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5875-0424","authenticated-orcid":false,"given":"Eduard","family":"Mas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7384-0103","authenticated-orcid":false,"given":"Lucia","family":"Molinero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M","family":"Pericas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2026.102477_bib0001","doi-asserted-by":"crossref","unstructured":"Lazarus JV, Miralles-Sanchez JE, Agirre-Garrido L, Brachowicz N, Nicol\u00e0s A, Armenta A Jr, et al. A call to action to address the steatotic liver disease public health threat in Barcelona. Lancet Reg Health Eur. 2025 Mar 22;52: 101272. doi: 10.1016\/j.lanepe.2025.101272.","DOI":"10.1016\/j.lanepe.2025.101272"},{"issue":"3","key":"10.1016\/j.aohep.2026.102477_bib0002","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102477_bib0003","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mcna.2017.08.012","article-title":"Maintenance of Lost Weight and Long-Term Management of Obesity","volume":"102","author":"Hall","year":"2018","journal-title":"Med Clin North Am"},{"issue":"6","key":"10.1016\/j.aohep.2026.102477_bib0004","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.aohep.2026.102477_bib0005","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.aohep.2026.102477_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101777","article-title":"From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Zhou","year":"2025","journal-title":"Ann Hepatol"},{"issue":"10","key":"10.1016\/j.aohep.2026.102477_bib0007","doi-asserted-by":"crossref","first-page":"20704","DOI":"10.3390\/ijms141020704","article-title":"Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)","volume":"14","author":"Takaki","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.aohep.2026.102477_bib0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"5","key":"10.1016\/j.aohep.2026.102477_bib0009","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.aohep.2026.102477_bib0010","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.aohep.2026.102477_bib0011","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13578-024-01267-9","article-title":"New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease","volume":"14","author":"Zhang","year":"2024","journal-title":"Cell Biosci"},{"issue":"4","key":"10.1016\/j.aohep.2026.102477_bib0012","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s13679-017-0280-9","article-title":"Food for Thought: Reward Mechanisms and Hedonic Overeating in Obesity","volume":"6","author":"Lee","year":"2017","journal-title":"Curr Obes Rep"},{"issue":"1","key":"10.1016\/j.aohep.2026.102477_bib0013","article-title":"FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models","volume":"12","author":"O'Farrell","year":"2022","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.aohep.2026.102477_bib0014","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102477_bib0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2025.01.032","article-title":"Sanyal AJ; ICONA Study Investigators. A phase IIb randomised-controlled trial of the FFAR1\/FFAR4 agonist icosabutate in MASH","volume":"83","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102477_bib0016","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-immunol-051116-052415","article-title":"Immune Responses in the Liver","volume":"36","author":"Kubes","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.aohep.2026.102477_bib0017","article-title":"Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.aohep.2026.102477_bib0018","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology (Baltimore MD)"},{"issue":"4","key":"10.1016\/j.aohep.2026.102477_bib0019","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jceh.2022.01.006","article-title":"Demonstration of Gut-Barrier Dysfunction in Early Stages of Non-alcoholic Fatty Liver Disease: A Proof-Of-Concept Study","volume":"12","author":"Kaushal","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102477_bib0020","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1124\/pharmrev.124.000978","article-title":"Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development","volume":"76","author":"Li","year":"2024","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.aohep.2026.102477_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1341938","article-title":"Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions","volume":"15","author":"Wei","year":"2024","journal-title":"Front Microbiol"},{"issue":"3","key":"10.1016\/j.aohep.2026.102477_bib0022","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2026.102477_bib0023","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En","year":"2023","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.aohep.2026.102477_bib0024","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl","key":"10.1016\/j.aohep.2026.102477_bib0025","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102477_bib0026","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102477_bib0027","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.aohep.2026.102477_bib0028","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.aohep.2026.102477_bib0029","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.aohep.2026.102477_bib0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.1016\/j.aohep.2026.102477_bib0031","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.aohep.2026.102477_bib0032","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.aohep.2026.102477_bib0033","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.aohep.2026.102477_bib0034","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","article-title":"Treating NASH by targeting peroxisome proliferator-activated receptors","volume":"79","author":"Staels","year":"2023","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2026.102477_bib0035","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.aohep.2026.102477_bib0036","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.aohep.2026.102477_bib0037","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102477_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.aohep.2026.102477_bib0039","doi-asserted-by":"crossref","unstructured":"Havranek B, Loh R, Torre B, Redfield R, Halegoua-DeMarzio D. Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes. Sci Rep. 2025 Feb 10;15(1):4947. doi: 10.1038\/s41598-025-89408-z.","DOI":"10.1038\/s41598-025-89408-z"},{"issue":"4","key":"10.1016\/j.aohep.2026.102477_bib0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102477_bib0041","doi-asserted-by":"crossref","first-page":"731","DOI":"10.4254\/wjh.v16.i5.731","article-title":"Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges","volume":"16","author":"Xie","year":"2024","journal-title":"World J Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2026.102477_bib0042","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.aohep.2026.102477_bib0043","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.clinthera.2008.08.006","article-title":"Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study","volume":"30","author":"Moretto","year":"2008","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.aohep.2026.102477_bib0044","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.aohep.2026.102477_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289616","article-title":"The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"18","author":"Liao","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.aohep.2026.102477_bib0046","doi-asserted-by":"crossref","unstructured":"Ghosal S, Datta D, Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep. 2021 Nov 11;11(1):22063. Doi:10.1038\/s41598-021-01663-y.","DOI":"10.1038\/s41598-021-01663-y"},{"issue":"10019","key":"10.1016\/j.aohep.2026.102477_bib0047","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.aohep.2026.102477_bib0048","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.aohep.2026.102477_bib0049","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.aohep.2026.102477_bib0050","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2337\/dc24-0764","article-title":"Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT","volume":"47","author":"Lingvay","year":"2024","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.aohep.2026.102477_bib0051","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.aohep.2026.102477_bib0052","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.aohep.2026.102477_bib0053","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.aohep.2026.102477_bib0054","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.aohep.2026.102477_bib0055","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.aohep.2026.102477_bib0056","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.aohep.2026.102477_bib0057","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2026.102477_bib0058","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"MK-6024 P001 Study Group. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Liu","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102477_bib0059","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2026.102477_bib0060","first-page":"S1","article-title":"Triple hormone receptor agonist retatrutide resolves steatosis in >85% of subjects with MASLD and obesity in association with improved metabolic health","volume":"78","author":"Sanyal","year":"2023","journal-title":"Hepatology"},{"issue":"10401","key":"10.1016\/j.aohep.2026.102477_bib0061","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.aohep.2026.102477_bib0062","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","article-title":"Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102477_bib0063","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis","volume":"59","author":"Harrison","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.aohep.2026.102477_bib0064","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"issue":"10504","key":"10.1016\/j.aohep.2026.102477_bib0065","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.aohep.2026.102477_bib0066","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in Compensated Liver Cirrhosis Caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.aohep.2026.102477_bib0067","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.aohep.2026.102477_bib0068","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(25)00067-6","article-title":"Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial","volume":"10","author":"Loomba","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"17","key":"10.1016\/j.aohep.2026.102477_bib0069","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.aohep.2026.102477_bib0070","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2026.102477_bib0071","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/gutjnl-2024-333485","article-title":"Treatment of type 2 diabetes with MASLD: new evidence for personalised medicine","volume":"74","author":"Caussy","year":"2025","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.aohep.2026.102477_bib0072","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2024-334023","article-title":"Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists","volume":"74","author":"Targher","year":"2025","journal-title":"Gut"},{"issue":"10296","key":"10.1016\/j.aohep.2026.102477_bib0073","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.aohep.2026.102477_bib0074","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","article-title":"Gut hormone co-agonists for the treatment of obesity: from bench to bedside","volume":"5","author":"Nogueiras","year":"2023","journal-title":"Nat Metab"},{"issue":"10390","key":"10.1016\/j.aohep.2026.102477_bib0075","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2026.102477_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.aohep.2026.102477_bib0077","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","article-title":"Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes","volume":"136","author":"El-Serag","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.aohep.2026.102477_bib0078","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.aohep.2026.102477_bib0079","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD","volume":"82","author":"Barb","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102477_bib0080","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.aohep.2026.102477_bib0081","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH\/NASH and Moderate to Noncirrhotic Advanced Fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102477_bib0082","article-title":"Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance","author":"Bansal","year":"2025","journal-title":"Hepatology"},{"issue":"25","key":"10.1016\/j.aohep.2026.102477_bib0083","article-title":"Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic dysfunction-associated Steatotic Liver Disease in Clinical Practice","author":"Olveira","year":"2025","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126002978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126002978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:07:49Z","timestamp":1793318869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268126002978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":83,"alternative-id":["S1665268126002978"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102477","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy for MASLD: current evidence and challenges in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102477"}}